PL1843771T3 - Zastosowanie pirymidyloaminobenzamidów do leczenia chorób odpowiadających na modulację aktywności kinazy Tie-2 - Google Patents

Zastosowanie pirymidyloaminobenzamidów do leczenia chorób odpowiadających na modulację aktywności kinazy Tie-2

Info

Publication number: PL1843771T3
Authority: PL; Poland
Prior art keywords: respond; modulation; diseases; tie; treatment
Prior art date: 2005-01-28

Application number

PL06706432T

Other languages

English (en)

Inventor

Paul W Manley

Georg Martiny-Baron

Juergen Mestan

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-01-28

Filing date

2006-01-26

Publication date

2012-02-29

2006-01-26 Application filed by Novartis Ag filed Critical Novartis Ag

2012-02-29 Publication of PL1843771T3 publication Critical patent/PL1843771T3/pl

Links

230000000694 effects Effects 0.000 title abstract 4
101100481410 Mus musculus Tek gene Proteins 0.000 title abstract 3
201000010099 disease Diseases 0.000 title abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
238000011282 treatment Methods 0.000 title abstract 2
201000003793 Myelodysplastic syndrome Diseases 0.000 abstract 1
108091000080 Phosphotransferase Proteins 0.000 abstract 1
102000001253 Protein Kinase Human genes 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
238000009109 curative therapy Methods 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
208000032839 leukemia Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
102000020233 phosphotransferase Human genes 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
108060006633 protein kinase Proteins 0.000 abstract 1
208000002815 pulmonary hypertension Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)

PL06706432T 2005-01-28 2006-01-26 Zastosowanie pirymidyloaminobenzamidów do leczenia chorób odpowiadających na modulację aktywności kinazy Tie-2 PL1843771T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US64789505P	2005-01-28	2005-01-28
US66240405P	2005-03-16	2005-03-16
EP06706432A EP1843771B1 (en)	2005-01-28	2006-01-26	Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity
PCT/EP2006/000686 WO2006079539A2 (en)	2005-01-28	2006-01-26	Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity

Publications (1)

Publication Number	Publication Date
PL1843771T3 true PL1843771T3 (pl)	2012-02-29

Family

ID=36273382

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL06706432T PL1843771T3 (pl)	2005-01-28	2006-01-26	Zastosowanie pirymidyloaminobenzamidów do leczenia chorób odpowiadających na modulację aktywności kinazy Tie-2

Country Status (17)

Country	Link
US (1)	US20080114001A1 (pl)
EP (1)	EP1843771B1 (pl)
JP (2)	JP5373288B2 (pl)
KR (2)	KR101325424B1 (pl)
CN (1)	CN101203224B (pl)
AT (1)	ATE525073T1 (pl)
AU (1)	AU2006208638B2 (pl)
BR (1)	BRPI0606872A2 (pl)
CA (1)	CA2594687C (pl)
CY (1)	CY1112568T1 (pl)
DK (1)	DK1843771T3 (pl)
ES (1)	ES2373912T3 (pl)
MX (1)	MX2007009135A (pl)
PL (1)	PL1843771T3 (pl)
PT (1)	PT1843771E (pl)
RU (1)	RU2404776C2 (pl)
WO (1)	WO2006079539A2 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2450814C2 (ru) *	2005-12-06	2012-05-20	Новартис Аг	Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза
US8093259B2 (en)	2006-05-25	2012-01-10	Novartis Ag	4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]-benzamide for treatment of melanoma
EP1923053A1 (en) *	2006-09-27	2008-05-21	Novartis AG	Pharmaceutical compositions comprising nilotinib or its salt
US8242271B2 (en)	2007-06-04	2012-08-14	Avila Therapeutics, Inc.	Heterocyclic compounds and uses thereof
KR20110053354A (ko) *	2008-08-13	2011-05-20	노파르티스 아게	폐동맥 고혈압의 치료
US9207782B2 (en)	2010-12-16	2015-12-08	Lg Electronics Inc.	Remote controller, remote controlling method and display system having the same
EP3956021A4 (en) *	2019-04-18	2023-06-14	EyePoint Pharmaceuticals, Inc.	METHOD OF TREATMENT OF HIGH BLOOD PRESSURE WITH ACTIVATORS OF TIE-2

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69429078T2 (de) *	1993-10-01	2002-07-11	Novartis Ag, Basel	Pharmacologisch wirksame pyridinderivate und verfahren zu deren herstellung
MY129541A (en) *	1996-06-25	2007-04-30	Novartis Ag	Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
PL352680A1 (pl) *	1999-06-03	2003-09-08	Knoll Gmbh	Związki benzotiazynonu i benzoksazynonu
US20030199525A1 (en) *	2002-03-21	2003-10-23	Hirst Gavin C.	Kinase inhibitors
GB0215676D0 (en)	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
GB0222514D0 (en) *	2002-09-27	2002-11-06	Novartis Ag	Organic compounds
JP4942297B2 (ja) *	2002-10-25	2012-05-30	ジアドミニストレイターズオブザチューレンエデュケイショナルファンド	肺高血圧症の処置を目的としたｎ−｛５−［４−（４−メチルピペラジノメチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリジン−アミンの使用
AU2004229392A1 (en) *	2003-04-09	2004-10-28	Exelixis, Inc.	Tie-2 modulators and methods of use
KR100976076B1 (ko) *	2003-05-22	2010-08-17	아보트 러보러터리즈	인다졸, 벤즈이속사졸 및 벤즈이소티아졸 키나제 억제제
WO2004108672A1 (en) *	2003-06-02	2004-12-16	Abbott Laboratories	Isoindolin-1-one compounds as kinase inhibitors
AR045037A1 (es) *	2003-07-10	2005-10-12	Aventis Pharma Sa	Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
GB0325031D0 (en) *	2003-10-27	2003-12-03	Novartis Ag	Organic compounds

2006
- 2006-01-26 PT PT06706432T patent/PT1843771E/pt unknown
- 2006-01-26 AT AT06706432T patent/ATE525073T1/de active
- 2006-01-26 BR BRPI0606872-3A patent/BRPI0606872A2/pt not_active IP Right Cessation
- 2006-01-26 KR KR1020077017223A patent/KR101325424B1/ko not_active Expired - Fee Related
- 2006-01-26 RU RU2007132255/15A patent/RU2404776C2/ru not_active IP Right Cessation
- 2006-01-26 JP JP2007552578A patent/JP5373288B2/ja not_active Expired - Fee Related
- 2006-01-26 MX MX2007009135A patent/MX2007009135A/es active IP Right Grant
- 2006-01-26 DK DK06706432.9T patent/DK1843771T3/da active
- 2006-01-26 CN CN2006800032580A patent/CN101203224B/zh not_active Expired - Fee Related
- 2006-01-26 EP EP06706432A patent/EP1843771B1/en not_active Expired - Lifetime
- 2006-01-26 US US11/815,046 patent/US20080114001A1/en not_active Abandoned
- 2006-01-26 CA CA2594687A patent/CA2594687C/en not_active Expired - Fee Related
- 2006-01-26 AU AU2006208638A patent/AU2006208638B2/en not_active Ceased
- 2006-01-26 WO PCT/EP2006/000686 patent/WO2006079539A2/en not_active Ceased
- 2006-01-26 KR KR1020137019492A patent/KR20130100371A/ko not_active Ceased
- 2006-01-26 ES ES06706432T patent/ES2373912T3/es not_active Expired - Lifetime
- 2006-01-26 PL PL06706432T patent/PL1843771T3/pl unknown
2011
- 2011-11-24 CY CY20111101146T patent/CY1112568T1/el unknown
2013
- 2013-07-04 JP JP2013140891A patent/JP2013213042A/ja active Pending

Also Published As

Publication number	Publication date
KR20130100371A (ko)	2013-09-10
CY1112568T1 (el)	2016-02-10
MX2007009135A (es)	2007-09-06
ES2373912T3 (es)	2012-02-10
EP1843771B1 (en)	2011-09-21
JP2008528531A (ja)	2008-07-31
DK1843771T3 (da)	2012-01-16
KR20070104567A (ko)	2007-10-26
US20080114001A1 (en)	2008-05-15
BRPI0606872A2 (pt)	2009-07-21
EP1843771A2 (en)	2007-10-17
AU2006208638B2 (en)	2010-03-04
CA2594687A1 (en)	2006-08-03
CN101203224B (zh)	2010-11-03
ATE525073T1 (de)	2011-10-15
JP5373288B2 (ja)	2013-12-18
CN101203224A (zh)	2008-06-18
RU2404776C2 (ru)	2010-11-27
KR101325424B1 (ko)	2013-11-04
CA2594687C (en)	2013-10-29
WO2006079539A3 (en)	2007-11-29
PT1843771E (pt)	2011-12-02
RU2007132255A (ru)	2009-03-10
AU2006208638A1 (en)	2006-08-03
JP2013213042A (ja)	2013-10-17
WO2006079539A2 (en)	2006-08-03

Publication	Publication Date	Title
UA98629C2 (ru)	2012-06-11	Соединения и способ модуляции киназ
JO2764B1 (en)	2014-03-15	Indole derivatives or benzimidazole derivatives to modify the enzyme AKP kinase
WO2005067546A3 (en)	2006-12-07	Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
GEP20115283B (en)	2011-09-12	Pyrrolopyrimidine compounds and their uses
WO2003080582A3 (de)	2004-12-09	Fredericamycin-derivate
AP2378A (en)	2012-03-08	Sulfonamide derivatives for the treatment of diseases.
MXPA05008478A (es)	2005-10-18	Heterociclos sustituidos.
TNSN08400A1 (en)	2010-04-14	Organic compounds and their uses
ATE453642T1 (de)	2010-01-15	Substituierte phenylaminopyrimidine
AP2359A (en)	2012-01-30	Sulfonamide derivatives for the treatment of diseases.
WO2009071689A3 (de)	2009-07-23	5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
MX2007002470A (es)	2009-02-12	Fenilaminotiazoles sustituidos y su uso.
CY1112568T1 (el)	2016-02-10	Χρηση των πυριμιδυλαμινοβενζαμιδων για τη θεραπεια των νοσων που ανταποκρινονται στην ρυθμιση της δρασης της τιε-2 κινασης
WO2005086656A3 (en)	2005-12-29	Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
TNSN07440A1 (en)	2009-03-17	Derivatives of pyrido [2,3 -d] pyrimidine, the preparation thereof, and the therapeutic application of the same
ATE475651T1 (de)	2010-08-15	Aryl-substituierte heterozyklen und ihre verwendung
WO2007016338A3 (en)	2007-12-21	Use of chk2 kinase inhibitors for cancer treatment
NO20080037L (no)	2008-01-03	Kombinasjon av pyrimidylaminobenzamidforbindelser og imatinib for behandling eller forbyggelse av proliferative sykdommer
IL178261A0 (en)	2006-12-31	Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
ATE380188T1 (de)	2007-12-15	Substituierte chinolone
WO2006023843A3 (en)	2007-02-08	Novel heterocycles
DE602006003094D1 (de)	2008-11-20	4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
IS2849B (is)	2013-09-15	Notkun á írbesartani til framleiðslunnar á lyfjum sem eru notuð til að fyrirbyggja eða meðhöndla lungnaháþrýsting
WO2006089664A3 (de)	2006-11-02	Heterocyclylamid-substituierte imidazole
UA85187C2 (en)	2009-01-12	2-aminobenzoyl derivatives